Arcutis shares up on news of public, private offerings

Arcutis Biotherapeutics saw a 15 percent rise in its share price after it said Sept. 29 that it will offer 4 million shares to the public and sell another $35 million in stock to an affiliate of one of its directors. Arcutis closed at $31.04, a gain of $4.28 after it announced the dual track Read More →

VCMC heals its finances

This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Cure closes $20M CBD acquisition

Cure Pharmaceutical, an Oxnard cannabis products manufacturer, has completed its $20 million cash-and-stock buyout of the CBD company Sera Labs, a deal Cure says will help it reach positive cash flow in around 18 months. Cure’s stock, which is traded on the over-the-counter markets, fell 3 percent following the announcement, closing at $1.29 per share Read More →
Amgen to team with Eli Lilly on COVID treatment

Thousand Oaks biotech giant Amgen announced another strategy to help address the coronavirus pandemic, entering into a manufacturing agreement with Eli Lilly to produce COVID-19 antibodies. Eli Lilly, based in Indianapolis, has been pursuing several antibody treatments for the virus, the two companies said in a Sept. 17 news release. With access to Amgen’s manufacturing Read More →
Public health officials are our COVID commanders
By Angela Hart As a veteran who served back-to-back tours in Iraq, I initially cringed when commentators compared the COVID-19 crisis to wartime — no bullets, no blood and no one volunteered for this. But after my months of reporting on the pandemic, it has become painfully clear this is like war. People are dying Read More →